Orthofix Medical Inc. filings document regulatory disclosures for a medical technology company focused on spinal implants, therapeutic solutions, limb reconstruction systems, biologics and enabling technologies. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales, guidance-related exhibits and non-GAAP measures including constant currency, free cash flow, adjusted gross profit and adjusted margin.
The company’s proxy and governance filings cover director elections, executive compensation, equity award disclosures, auditor ratification and common-share voting matters. Other current reports document Spine leadership changes, annual meeting results and board committee appointments.
Orthofix Medical (OFIX) filed a Form 4 disclosing that director Charles R. Kummeth was granted 18,841 deferred stock units (DSUs) on 06/18/2025 at no cost. The DSUs vest in full on the first anniversary of the grant date and will convert into common stock within 45 days after his service with the company ends. Following the award, Kummeth’s total beneficial ownership rose to 59,237 shares, which now includes 23,502 previously reported DSUs and 1,894 shares accumulated through Orthofix’s Stock Purchase Plan.
Orthofix Medical Inc. (OFIX) – Form 4 insider filing dated 06/23/2025
Director John B. Henneman III reported a single equity-compensation transaction that occurred on 06/18/2025.
- Securities granted: 18,841 deferred stock units (DSUs) coded “A” (award).
- Price: $0, confirming the grant was part of the company’s director compensation plan rather than an open-market purchase or sale.
- Vesting schedule: DSUs vest 100 % on the first anniversary of the grant provided the director continues in service. Each DSU converts into one share of common stock within 45 days after the director’s service ends.
- Post-transaction beneficial ownership: 83,706 OFIX common shares, comprising the newly granted 18,841 DSUs, 29,506 previously reported DSUs, and 951 shares acquired under the Orthofix Stock Purchase Plan on 04/30/2025.
- The filing was executed by attorney-in-fact J. Andres Cedron and submitted on 06/23/2025.
No derivative securities were reported in Table II, and the filing indicates a single reporting person with director status. The form contains no indication of a 10b5-1 trading plan and no amendments to earlier filings.
Orthofix Medical Inc. (OFIX) filed a Form 8-K reporting the results of its 18 June 2025 Annual Meeting of Shareholders.
Quorum: 35,364,307 of 39,180,306 eligible shares were present, comfortably exceeding the 19,590,154-share quorum requirement.
Director elections: All ten nominees—Alan L. Bazaar, Wayne Burris, Massimo Calafiore, Vickie L. Capps, Michael M. Finegan, Jason M. Hannon, John B. Henneman III, Charles R. Kummeth, Shweta Singh Maniar and Michael E. Paolucci—were elected for one-year terms ending at the 2026 meeting. Each candidate received substantially more “For” than “Against” votes.
Say-on-Pay: The advisory resolution approving executive compensation passed with 30,003,045 votes in favour versus 610,731 against and 9,569 abstentions.
Auditor ratification: Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2025 (35,017,551 votes in favour; 329,289 against; 17,467 abstentions).
Board committee appointments: Effective immediately, the Board unanimously appointed director Vickie L. Capps to the Audit & Finance Committee and to the Compensation & Talent Development Committee.
The filing contains no financial results, strategic transactions or other material events beyond routine governance disclosures.